These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15696549)

  • 1. Cost-effectiveness analysis: out of touch with clinical reality?
    Maetzel A
    Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

  • 4. Now that we know what's BeSt, what is good value for the money?
    Bansback N; Marra CA
    Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126
    [No Abstract]   [Full Text] [Related]  

  • 5. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing model structures in cost-effectiveness analysis.
    Russell LB
    Med Decis Making; 2005; 25(5):485-6. PubMed ID: 16160203
    [No Abstract]   [Full Text] [Related]  

  • 10. It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.
    O'Dell JR
    Arthritis Rheum; 2007 Dec; 56(12):3884-6. PubMed ID: 18050217
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab cost-effectiveness/safety?
    Rothschild BM
    Rheumatology (Oxford); 2003 Dec; 42(12):1572-3; author reply 1573-4. PubMed ID: 14645868
    [No Abstract]   [Full Text] [Related]  

  • 12. Rheumatoid arthritis.
    Sutor SM; Gricar JA; Cave DG
    Manag Care Interface; 1999 Jun; 12(6):51-3. PubMed ID: 10538460
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of biologics in early rheumatoid arthritis.
    Finckh A; Bansback N; Liang MH
    Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
    van der Velde G; Pham B; Machado M; Ieraci L; Witteman W; Bombardier C; Krahn M
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):65-78. PubMed ID: 20740606
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    van Vollenhoven RF;
    Rheumatology (Oxford); 2008 Jul; 47(7):1106-7; author reply 1107. PubMed ID: 18326533
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies.
    Lipsky PE; Kavanaugh A
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():41-4. PubMed ID: 10646490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.
    Welsing PM; Severens JL; Laan RF
    Rheumatology (Oxford); 2003 Dec; 42(12):1574-5; author reply 1573-4. PubMed ID: 14645870
    [No Abstract]   [Full Text] [Related]  

  • 18. Bibliography. Current world literature. Clinical therapeutics.
    Curr Opin Rheumatol; 2007 May; 19(3):314-9. PubMed ID: 17414962
    [No Abstract]   [Full Text] [Related]  

  • 19. An excellent example of an early arthritis clinic -- what is its clinical value?
    Sokka T; Mäkinen H
    J Rheumatol; 2009 Jul; 36(7):1355-6. PubMed ID: 19567630
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient access to rheumatoid arthritis treatments.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S33-4. PubMed ID: 18097698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.